Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade
David
D
Department of Medical and Molecular Genetics, King's College London School of Medicine, London, UK. david.grimwade@genetics.kcl.ac.uk
Mistry
Anita R
AR
Solomon
Ellen
E
Guidez
Fabien
F
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D004417:Dyspnea / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D007964:Leukocytosis / Q000139:chemically induced; D008954:Models, Biological; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000502:physiology; D010087:Oxides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014158:Transcription, Genetic; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D000077237:Arsenic Trioxide